---
title: "Standard BioTools Inc. Announces New RSU Retention Awards and Increased Performance Bonus Target for Executives"
description: "Standard BioTools Inc. has announced new compensation terms for its executives, effective August 1, 2025. The Board approved RSU retention awards for CEO Michael Egholm (3,000,000 RSUs) and CFO Alex K"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251248742.md"
published_at: "2025-08-01T20:21:36.000Z"
---

# Standard BioTools Inc. Announces New RSU Retention Awards and Increased Performance Bonus Target for Executives

> Standard BioTools Inc. has announced new compensation terms for its executives, effective August 1, 2025. The Board approved RSU retention awards for CEO Michael Egholm (3,000,000 RSUs) and CFO Alex Kim (1,500,000 RSUs), with specific vesting schedules. Additionally, Kim's annual performance bonus target has been increased to 80% of his base salary, retroactively effective from January 1, 2025. These changes align with the company's Change of Control and Severance Plans.

Standard BioTools Inc. has announced new compensation terms for its key executives, effective August 1, 2025. The company’s Board of Directors has approved restricted stock unit (RSU) retention awards for Michael Egholm, Ph.D., President & CEO, and Alex Kim, CFO, as part of the Amended and Restated 2011 Equity Incentive Plan. Dr. Egholm will receive 3,000,000 RSUs, with 25% vesting on August 1, 2026, and the remainder vesting in equal annual installments over the following three years. Mr. Kim is set to receive 1,500,000 RSUs, with 40% vesting on July 20, 2026, and the remaining 60% vesting on July 20, 2027. Additionally, Mr. Kim’s annual performance bonus target has been increased to 80% of his base salary, retroactively effective from January 1, 2025. These awards are aligned with the company’s 2023 and 2024 Change of Control and Severance Plans. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-101439), on August 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [LAB.US - Standard BioTools](https://longbridge.com/en/quote/LAB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Labat Africa Approves Share Repurchase Up To 20% Of Capital | Labat Africa Ltd :LABAT AFRICA - APPROVES SHARE REPURCHASE UP TO 20% OF CAPITAL | [Link](https://longbridge.com/en/news/275772528.md) |
| Codeifai Enters AI-Backed Quantum Security Market | Codeifai Ltd :CODEIFAI ENTERS AI-BACKED QUANTUM SECURITY MARKETCOMPLETION OF ACQUISITION OF ANTENNATRANSFER.IOTOTAL CONS | [Link](https://longbridge.com/en/news/276015719.md) |
| Short Interest in Garmin Ltd. (NYSE:GRMN) Increases By 33.2% | Garmin Ltd. (NYSE:GRMN) experienced a 33.2% increase in short interest in January, totaling 3,028,012 shares as of Janua | [Link](https://longbridge.com/en/news/276018254.md) |
| Electrovaya Inc. (NASDAQ:ELVA) Short Interest Update | Electrovaya Inc. (NASDAQ:ELVA) experienced a 24.6% decline in short interest in January, with 334,380 shares short as of | [Link](https://longbridge.com/en/news/276018408.md) |
| Melco Resorts & Entertainment (MLCO) Is Down 12.9% After Return To Quarterly Profitability And Record Five-Star Awards | Melco Resorts & Entertainment reported a Q4 2025 revenue of $1.29 billion, swinging to a $60.64 million profit from a pr | [Link](https://longbridge.com/en/news/276002958.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.